Larimar Therapeutics Aktie

Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025.» Mehr auf seekingalpha.com

On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.» Mehr auf benzinga.com

Citi analyst Samantha Semenkow notes Larimar Therapeutics announced initial data from the ongoing long-term Open Label Extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp and calls the market's negative reaction to the disclosure "at odds with what we view as a very positive dataset." The firm, which believes the market is "misinterpreting the two reported SAEs that led to discontinuations as a signal of a broader safety issue," believes the longer-term safety data reported today begin to confirm that nomlabofusp is safe and tolerable for chronic dosing. The firm, which views today's selloff as "overdone," would be "buyers on the dip" and maintains a Buy rating and $14 price target on Larimar shares.» Mehr auf thefly.com